Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab in RA inadequately controlled by TNF-alpha inhibitors
NCT02760433Phase 3Completed
- Sponsor
- R-Pharm
- Start
- Jan 2017
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of olokizumab in rheumatoid arthritis (RA), sponsored by R-Pharm. Started Jan 2017; status: completed.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02760433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760433.